Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$10.9 million.

  • Cardiff Oncology's Free Cash Flow fell 378.73% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year decrease of 2197.21%. This contributed to the annual value of -$37.8 million for FY2024, which is 2003.24% down from last year.
  • Latest data reveals that Cardiff Oncology reported Free Cash Flow of -$10.9 million as of Q3 2025, which was down 378.73% from -$7.5 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Free Cash Flow peaked at -$4.3 million during Q2 2021, and registered a low of -$13.7 million during Q1 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$7.9 million (2022), whereas its average is -$8.4 million.
  • In the last 5 years, Cardiff Oncology's Free Cash Flow tumbled by 7709.04% in 2022 and then skyrocketed by 2449.02% in 2023.
  • Cardiff Oncology's Free Cash Flow (Quarter) stood at -$7.5 million in 2021, then fell by 26.25% to -$9.5 million in 2022, then grew by 24.49% to -$7.1 million in 2023, then plummeted by 43.65% to -$10.3 million in 2024, then decreased by 5.7% to -$10.9 million in 2025.
  • Its Free Cash Flow was -$10.9 million in Q3 2025, compared to -$7.5 million in Q2 2025 and -$13.7 million in Q1 2025.